February 10, 2025
Jazz Pharmaceuticals Inc. has reached an agreement to dismiss all claims and counterclaims with the last remaining defendant in its consolidated lawsuits over patents covering its epilepsy treatment Epidiolex, according to a filing from the company in New Jersey federal court.
January 11, 2024
A New Jersey federal judge on Thursday dismissed allegations that 19 Jazz Pharmaceuticals patents covering its epilepsy treatment Epidiolex aren't enforceable, saying there's no evidence that the company lied to the patent office to dodge higher fees.
July 18, 2023
British pharmaceutical firm GW Pharmaceuticals has urged a New Jersey federal judge to toss counterclaims lodged by InvaGen Pharmaceuticals in a patent dispute regarding GW's flagship CBD-derived epilepsy treatment Epidiolex.
January 05, 2023
British pharmaceutical firm GW Pharmaceuticals has accused a dozen drug manufacturers, including Teva Pharmaceuticals, of violating its patents when they sought approval to sell generic versions of the company's flagship CBD-derived epilepsy treatment Epidiolex.